Browsing Over 57 Sessions

Sort By

MSD - Transforming the Adjuvant Treatment Paradigm in Melanoma (ID 111)

Time
08:45 - 10:15

Novartis - Navigating the Current Treatment Landscape in Esophageal Cancer with an Eye Toward the Future (ID 112)

Time
08:45 - 10:15

MSD - Implementation of Immunotherapy in the First-Line Treatment of Esophageal, Gastroesophageal Junction and Gastric Cancers (ID 113)

Time
08:45 - 10:15

Pfizer Oncology - Expert Perspectives in ALK+NSCLC: a round table discussion (ID 110)

Time
08:45 - 09:45

Amgen - Precision therapy in NSCLC: the dawn of KRAS G12C inhibition   (ID 115)

Time
10:30 - 12:00

Seagen - Navigating a new era in HER2+ metastatic breast cancer: Focus on HER2CLIMB  (ID 116)

Time
10:30 - 12:00

Pfizer Oncology - Complex Management of Relapsed and Refractory Multiple Myeloma (RRMM) and Evaluation of Unmet Needs (ID 117)

Time
10:30 - 12:00

Pfizer Oncology - Confidence and clarity in advanced breast cancer: Insights from the real world  (ID 114)

Time
10:30 - 12:00

Janssen - Expanding horizons for the targeted management of EGFR-Positive NSCLC (ID 119)

Time
18:45 - 20:15

Takeda - Illuminating the Path Forward in EGFR Exon20 Insertion+ mNSCLC: Unmet Needs and the Evolving Treatment Landscape  (ID 121)

Time
18:45 - 20:15

Daiichi Sankyo - Advances in Antibody Drug Conjugates in Solid Tumors: Current Treatments and Emerging Therapies  (ID 118)

Time
18:45 - 20:15

AbbVie, Inc. - A Novel Approach to Targeting c-Met in Lung Cancer (ID 124)

Time
08:45 - 10:15